January 13, 2017
Shionogi said on January 12 that its novel siderophore cefiderocol injection (development code: S-649266) showed superiority to imipenem/cilastatin at test of cure (TOC) in a global study in patients with serious complicated urinary tract infection (cUTI) with Gram-negative bacteria. The...read more